• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASGR1: an emerging therapeutic target in hypercholesterolemia.

作者信息

Zhao Wenqi, Xu Suowen, Weng Jianping

机构信息

Department of Endocrinology, Institute of Endocrine and Metabolic Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Clinical Research Hospital of Chinese Academy of Sciences (Hefei), University of Science and Technology of China, Hefei, 230027, China.

出版信息

Signal Transduct Target Ther. 2023 Jan 23;8(1):43. doi: 10.1038/s41392-023-01319-5.

DOI:10.1038/s41392-023-01319-5
PMID:36690631
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9869305/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7762/9871030/4279373985d9/41392_2023_1319_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7762/9871030/4279373985d9/41392_2023_1319_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7762/9871030/4279373985d9/41392_2023_1319_Fig1_HTML.jpg

相似文献

1
ASGR1: an emerging therapeutic target in hypercholesterolemia.去唾液酸糖蛋白受体1：高胆固醇血症中一个新兴的治疗靶点。
Signal Transduct Target Ther. 2023 Jan 23;8(1):43. doi: 10.1038/s41392-023-01319-5.
2
In silico discovery of food-derived phytochemicals against asialoglycoprotein receptor 1 for treatment of hypercholesterolemia: Pharmacophore modeling, molecular docking and molecular dynamics simulation approach.基于药效团模型、分子对接和分子动力学模拟方法的抗血清类黏蛋白受体 1 的食物源植物化学物治疗高胆固醇血症的计算机发现
J Mol Graph Model. 2023 Dec;125:108614. doi: 10.1016/j.jmgm.2023.108614. Epub 2023 Aug 25.
3
Beyond conventional treatment: ASGR1 Leading the new era of hypercholesterolemia management.超越传统治疗：ASGR1 引领高胆固醇血症管理新时代。
Biomed Pharmacother. 2024 Nov;180:117488. doi: 10.1016/j.biopha.2024.117488. Epub 2024 Sep 23.
4
Deficiency of ASGR1 in pigs recapitulates reduced risk factor for cardiovascular disease in humans.猪的 ASGR1 缺乏可重现人类心血管疾病风险因素降低。
PLoS Genet. 2021 Nov 11;17(11):e1009891. doi: 10.1371/journal.pgen.1009891. eCollection 2021 Nov.
5
Porcine extrahepatic vascular endothelial asialoglycoprotein receptor 1 mediates xenogeneic platelet phagocytosis in vitro and in human-to-pig ex vivo xenoperfusion.猪肝外血管内皮去唾液酸糖蛋白受体1在体外及人到猪的离体异种灌注中介导异种血小板吞噬作用。
Transplantation. 2015 Apr;99(4):693-701. doi: 10.1097/TP.0000000000000553.
6
Reduced human platelet uptake by pig livers deficient in the asialoglycoprotein receptor 1 protein.缺乏去唾液酸糖蛋白受体1蛋白的猪肝对人血小板摄取减少。
Xenotransplantation. 2015 May-Jun;22(3):203-10. doi: 10.1111/xen.12164. Epub 2015 Feb 27.
7
Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin.Asialoglycoprotein 受体 1 是一种新型的 PCSK9 非依赖性配体，可被弗林蛋白酶切割肝脏 LDLR。
J Biol Chem. 2021 Oct;297(4):101177. doi: 10.1016/j.jbc.2021.101177. Epub 2021 Sep 8.
8
Asialoglycoprotein Receptor 1 Functions as a Tumor Suppressor in Liver Cancer via Inhibition of STAT3.Asialoglycoprotein Receptor 1 通过抑制 STAT3 发挥肝癌肿瘤抑制因子的作用。
Cancer Res. 2022 Nov 2;82(21):3987-4000. doi: 10.1158/0008-5472.CAN-21-4337.
9
The asialoglycoprotein receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-mediated inhibition of V-ATPase activity.去唾液酸糖蛋白受体通过LASS2介导的V-ATP酶活性抑制作用抑制肝细胞癌的转移。
Cancer Lett. 2016 Aug 28;379(1):107-16. doi: 10.1016/j.canlet.2016.05.030. Epub 2016 May 27.
10
Potentiation of proliferation of some but not all human colon carcinoma cell lines by immobilized hepatic asialoglycoprotein receptor 1.固定化肝去唾液酸糖蛋白受体1对部分而非全部人结肠癌细胞系增殖的增强作用。
Oncol Res. 2009;17(10):437-45. doi: 10.3727/096504009789735440.

引用本文的文献

1
Large-Scale Plasma Proteomics to Profile Pathways and Prognosis of Chronic Pain.大规模血浆蛋白质组学分析慢性疼痛的通路和预后
Adv Sci (Weinh). 2025 Apr;12(16):e2410160. doi: 10.1002/advs.202410160. Epub 2025 Mar 6.
2
Boiling histotripsy exhibits anti-fibrotic effects in animal models of liver fibrosis.煮沸声化学处理在肝纤维化动物模型中表现出抗纤维化作用。
Sci Rep. 2024 Jul 2;14(1):15099. doi: 10.1038/s41598-024-66078-x.
3
Deficiency of ASGR1 promotes liver injury by increasing GP73-mediated hepatic endoplasmic reticulum stress.

本文引用的文献

1
Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion.抑制 ASGR1 通过促进胆固醇排泄来降低血脂水平。
Nature. 2022 Aug;608(7922):413-420. doi: 10.1038/s41586-022-05006-3. Epub 2022 Aug 3.
2
Deficiency of ASGR1 in pigs recapitulates reduced risk factor for cardiovascular disease in humans.猪的 ASGR1 缺乏可重现人类心血管疾病风险因素降低。
PLoS Genet. 2021 Nov 11;17(11):e1009891. doi: 10.1371/journal.pgen.1009891. eCollection 2021 Nov.
3
Hypomorphic ASGR1 modulates lipid homeostasis via INSIG1-mediated SREBP signaling suppression.
ASGR1 缺乏通过增加 GP73 介导的肝内质网应激促进肝损伤。
Nat Commun. 2024 Mar 8;15(1):1908. doi: 10.1038/s41467-024-46135-9.
4
Advances in Pharmacological Approaches for Managing Hypercholesterolemia: A Comprehensive Overview of Novel Treatments.高胆固醇血症管理的药理学方法进展：新型治疗方法的全面概述
Biomedicines. 2024 Feb 14;12(2):432. doi: 10.3390/biomedicines12020432.
5
Drug development advances in human genetics-based targets.基于人类遗传学靶点的药物研发进展。
MedComm (2020). 2024 Feb 9;5(2):e481. doi: 10.1002/mco2.481. eCollection 2024 Feb.
功能获得性 ASGR1 通过 INSIG1 介导的 SREBP 信号抑制来调节脂质稳态。
JCI Insight. 2021 Oct 8;6(19):e147038. doi: 10.1172/jci.insight.147038.
4
ASGR1 and Its Enigmatic Relative, CLEC10A.ASGR1 及其神秘的同源物 CLEC10A。
Int J Mol Sci. 2020 Jul 8;21(14):4818. doi: 10.3390/ijms21144818.
5
Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease.ASGR1 变异与冠心病风险降低相关。
N Engl J Med. 2016 Jun 2;374(22):2131-41. doi: 10.1056/NEJMoa1508419. Epub 2016 May 18.